Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BY 4.0Cancers

Prognostic Significance of Nodal Burden According to ABO Blood Group in Stage II–III Breast Cancer: An Exploratory Analysis

  • Koji Tezuka1,2
  • Seiichiro Nishimura2
  • Tomomi Hayashi2
  • Emima Bekku2
  • Yukiko Tadokoro2
  • Rikako Yamamura2
  • Takayoshi Uematsu3
  • Kazuaki Nakashima3
  • Nahomi Tokudome4
  • Takashi Sugino5
  • Makoto Nagahara1
  • Kaoru Takahashi2
5 affiliations
  1. 1Department of Breast Surgery, JCHO Mishima General Hospital, Mishima 411-0801, Japan
  2. 2Department of Breast Surgery, Shizuoka Cancer Center, Nagaizumi 411-8777, Japan
  3. 3Department of Breast Imaging and Breast Interventional Radiology, Shizuoka Cancer Center, Nagaizumi 411-8777, Japan
  4. 4Department of Breast Oncology, Shizuoka Cancer Center, Nagaizumi 411-8777, Japan
  5. 5Department of Pathology, Shizuoka Cancer Center, Nagaizumi 411-8777, Japan
Open at sourceDOICite

Abstract

Background/Objectives: Previous studies of ABO blood group and breast cancer prognosis have yielded inconsistent results, mainly evaluating blood group itself as a prognostic factor. We investigated whether the prognostic associations of clinicopathological factors differ according to ABO blood group in stage II–III breast cancer. Methods: We retrospectively analyzed 1540 patients with stage II–III breast cancer who underwent curative resection between 2010 and 2019. Blood group-specific prognostic analyses of breast cancer-specific survival (BCSS) were performed, with continuous variables analyzed without dichotomization. Based on the observed patterns, an exploratory interaction between blood group B and pathological nodal status was tested, and its robustness was assessed using a permutation test and sensitivity analyses. Results: ABO blood group was not associated with BCSS overall (p = 0.641). In blood group-stratified multivariable analyses, ≥4 lymph node metastases was an independent adverse prognostic factor in blood groups A, O, and AB, but not in blood group B. A significant interaction was observed between blood group B and pathological nodal status (0–3 vs. ≥4 nodes) (p for interaction < 0.001; permutation-adjusted p = 0.004). Among patients with 0–3 lymph node metastases, blood group B was independently associated with worse BCSS (hazard ratio, 2.04; 95% confidence interval, 1.25–3.32; p = 0.004), consistently across sensitivity analyses; this association was more evident among patients who received neoadjuvant chemotherapy. In this subgroup, blood group B was also associated with more distant and visceral recurrence (all p < 0.05). Conclusions: The prognostic association of nodal burden in stage II–III breast cancer may differ according to ABO blood group. The exploratory findings in patients with limited nodal involvement suggest that blood group B may identify a subgroup characterized by worse BCSS and increased distant and visceral recurrence. Given the small number of events in blood group B with ≥4 nodes and possible differences according to neoadjuvant chemotherapy, these findings are hypothesis-generating and warrant independent validation.

Related

  1. Prognostic significance of CCT5 in breast cancer and its regulatory mechanisms in promoting tumorigenesis
    Jianwen Wang, Yuming Chen, Qiang Zhu +7
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  2. Prognostic Significance of p53 Immunohistochemical Expression and Molecular Characterization of TP53 Variants in Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
    Juan Ramón Berenguer-Marí, Luis Álvarez, Julia Sierra-Roca +8
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Receptor Status Changes, HER2-Low Discordance, and TNBC Transformation in Metastatic Breast Cancer: Prognostic Significance and Impact on Survival Outcomes
    Ayşe Nuransoy Cengiz, Muhammet Cengiz, Oktay Bozkurt +7
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. Clinical and prognostic significance of the C-reactive protein-albumin-lymphocyte (CALLY) index in breast cancer: a systematic review and meta-analysis
    K. Jalalian Rad, S. Kadri, A. Yakiti +4
    medRxivPreprintCC BY-NC-NDFull textOncologymedRxiv
  5. Prevalence and Prognostic Significance of Positron Emission Tomography–Computed Tomography–Defined Low Skeletal Muscle Mass (Radiological Sarcopenia) in Metastatic Breast Cancer
    Taliha Güçlü Kantar, Semra Taş, Tolga Doğan +9
    Cerrahpaşa Medical JournalPeer-reviewedCC BY-NCFull textPhysiologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{tezuka2026prognostic,
  title = {{Prognostic Significance of Nodal Burden According to ABO Blood Group in Stage II–III Breast Cancer: An Exploratory Analysis}},
  author = {Koji Tezuka and Seiichiro Nishimura and Tomomi Hayashi and Emima Bekku and Yukiko Tadokoro and Rikako Yamamura and Takayoshi Uematsu and Kazuaki Nakashima and Nahomi Tokudome and Takashi Sugino and Makoto Nagahara and Kaoru Takahashi},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18213448},
  url = {https://www.mdpi.com/2072-6694/18/21/3448},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Prognostic Significance of Nodal Burden According to ABO Blood Group in Stage II–III Breast Cancer: An Exploratory Analysis
AU  - Koji Tezuka
AU  - Seiichiro Nishimura
AU  - Tomomi Hayashi
AU  - Emima Bekku
AU  - Yukiko Tadokoro
AU  - Rikako Yamamura
AU  - Takayoshi Uematsu
AU  - Kazuaki Nakashima
AU  - Nahomi Tokudome
AU  - Takashi Sugino
AU  - Makoto Nagahara
AU  - Kaoru Takahashi
PY  - 2026
DA  - 2026/10/25
JO  - Cancers
DO  - 10.3390/cancers18213448
UR  - https://www.mdpi.com/2072-6694/18/21/3448
AB  - Background/Objectives: Previous studies of ABO blood group and breast cancer prognosis have yielded inconsistent results, mainly evaluating blood group itself as a prognostic factor. We investigated whether the prognostic associations of clinicopathological factors differ according to ABO blood group in stage II–III breast cancer. Methods: We retrospectively analyzed 1540 patients with stage II–III breast cancer who underwent curative resection between 2010 and 2019. Blood group-specific prognostic analyses of breast cancer-specific survival (BCSS) were performed, with continuous variables analyzed without dichotomization. Based on the observed patterns, an exploratory interaction between blood group B and pathological nodal status was tested, and its robustness was assessed using a permutation test and sensitivity analyses. Results: ABO blood group was not associated with BCSS overall (p = 0.641). In blood group-stratified multivariable analyses, ≥4 lymph node metastases was an independent adverse prognostic factor in blood groups A, O, and AB, but not in blood group B. A significant interaction was observed between blood group B and pathological nodal status (0–3 vs. ≥4 nodes) (p for interaction < 0.001; permutation-adjusted p = 0.004). Among patients with 0–3 lymph node metastases, blood group B was independently associated with worse BCSS (hazard ratio, 2.04; 95% confidence interval, 1.25–3.32; p = 0.004), consistently across sensitivity analyses; this association was more evident among patients who received neoadjuvant chemotherapy. In this subgroup, blood group B was also associated with more distant and visceral recurrence (all p < 0.05). Conclusions: The prognostic association of nodal burden in stage II–III breast cancer may differ according to ABO blood group. The exploratory findings in patients with limited nodal involvement suggest that blood group B may identify a subgroup characterized by worse BCSS and increased distant and visceral recurrence. Given the small number of events in blood group B with ≥4 nodes and possible differences according to neoadjuvant chemotherapy, these findings are hypothesis-generating and warrant independent validation.
SN  - 2072-6694
ER  -